在遗传性出血性电脉切开症中治疗心房动的抗血栓治疗
Zain M Virk1, T Lee Richardson1,2, Hanny Al-Samkari3,4
1Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Journal of thrombosis and thrombolysis
|June 20, 2023
概括
在遗传性出血性远程切除症 (HHT) 患者中,对心房的抗血栓治疗耐受性较差,往往需要减少剂量或停止治疗. 对于这个高风险群体,可能需要采用替代策略.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 遗传学 遗传学 是一个
背景情况:
- 心房动 (AF) 的管理需要抗血栓治疗来预防中风.
- 遗传性出血端膜切除症 (HHT) 患者由于血管形而增加出血风险.
- HHT患者也面临高血栓风险,复杂化AF治疗.
研究的目的:
- 研究HHT和AF患者抗血栓治疗的耐受性和结果.
- 确定这个特定患者群体的挑战和潜在的替代管理策略.
主要方法:
- 追溯队列研究的设计.
- 分析使用抗血栓治疗,剂量调整和停止在HHT患者的AF.
- 对接受左心房附属体手术的患者结果的综述.
主要成果:
- 在大多数患者和治疗情节中,抗血栓治疗的耐受性很差.
- 过早降低剂量或停止抗血栓治疗是常见的.
- 接受左心房附属体手术的5名患者忍受了治疗挑战,并取得了积极的结果.
结论:
- 对HHT和AF患者来说,抗血栓治疗存在显著的耐受性问题.
- 左心房尾阻塞或抗血管原性疗法可能需要进一步调查作为替代方案.
- 仔细考虑和个性化治疗计划对于管理HHT患者的AF至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
767
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
767
Venous Thrombosis III: Interprofessional Care
11
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
11
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis IV: Nursing Management
15
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
15
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
568
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
568
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
212
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
212


